Abstract:Objective To investigate the inhibition effects of CpG oligodeoxynucleotide(CpG ODN) on renal carcinoma cell proliferation and tumor growth in vivo and in vitro,and explore the possible mechanism.Methods The effects of different concentrations of CpG ODN1826 and non-CpG ODN1982(ODN1982) interventions on proliferation of human renal clear cell carcinoma cell line Caki-1 cultured in vitro were determined with CCK-8 method.Tumor-bearing nude mouse models were established by subcutaneous implantation of Caki-1 cells into 24 BALB/c mice,and were randomly divided into control group(PBS),ODN1982 group(50 μg ODN1982),low-dose CpG ODN1826 group(25 μg CpG ODN1826) and high-dose CpG ODN1826 group(50 μg CpG ODN1826) 4 d later according to means of weekly treatment,with 6 mice in each group.Mice were sacrificed 35 d after model establishment,and changes of tumor volumes,tumor weight and tumor histology were compared among groups.Splenic lymphocytes of tumor-bearing mice in each group were isolated in vitro,and lactate dehydrogenase release method was employed to detect the cytolytic activity of splenic lymphocytes of tumor-bearing mice to tumor cells with different effector/target ratios(splenic lymphocytes:Caki-1 cells or splenic lymphocytes:YAC-1 cells).Results ODN1982 had no significant effect on in vitro proliferation of Caki-1 cells,while 500 μg/mL CpG ODN1826 significantly inhibited proliferation of Caki-1 cells.The tumor volumes of low-dose CpG ODN1826 group and high-dose CpG ODN1826 group were significantly smaller than those of control group and ODN1982 group at the end point of experiment(P 0.05),and there were significant differences in tumor weight among groups(P 0.05).It was revealed by histological observations that there were more inflammatory cell infiltration in low-dose CpG ODN1826 group and high-dose CpG ODN1826 group.The cytolytic activity of splenic lymphocytes of mice in high-dose CpG ODN1826 group to Caki-1 cells and YAC-1 cells was(9.74 ± 1.16) % and(79.65 ± 5.23) %,respectively at effector/target ratio of 50:1,and was significantly higher than that in control group [(7.67 ± 0.22) % and(10.12 ± 3.03) %,respectively] and ODN1982 group [(7.66 ± 0.93) % and(27.60 ± 9.83) %,respectively](P 0.05).Conclusion CpG ODN can inhibit renal carcinoma cell proliferation in vitro and tumor growth in tumor-bearing nude mice,and the mechanism may relate to the enhancement of innate immunity by CpG ODN.

Immunostimulatory and Anti-Neoplasm Effects of a Novel Palindrome CpG Oligodeoxynucleotide in Mice

Anti-neoplasm and immuno-modification effect of novel CpG oligodeoxynucleotides in mice

Dddt_a_325790 3953..3963

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity in Vitro and Enhances Antitumor Effect in Vivo

[Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression]

CpG Oligodeoxynucleotides Enhance the Efficacy of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes by Modifying the Th1 Polarization and Local Infiltration of Th17 Cells

Cpg Oligodeoxynucleotide Developed To Activate Primate Immune Responses Promotes Antitumoral Effects In Combination With A Neoantigen-Based Mrna Cancer Vaccine

CpG Oligodeoxynucleotide Developed For Activating Primate Immune Responses Promotes Anti-Tumoral Effect Combine With Neo-Antigen Based mRNA Cancer Vaccine

[Antitumor Effect of CpG Oligonucleotides on Human Neuroblastoma Xenografts in Nude Mice].

CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials

Fully Phosphorothioate-Modified CpG ODN with PolyG Motif Inhibits the Adhesion of B16 Melanoma Cells in Vitro and Tumorigenesis in Vivo.

CpG-PEG Conjugates and Their Immune Modulating Effects after Systemic Administration

Delivery System of Cpg Oligodeoxynucleotides Through Eliciting an Effective T Cell Immune Response Against Melanoma in Mice

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.

Adcances in CpG oligodeoxynucleotides in the cancer immunotherapy

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice.

Structure-efficacy Relationships of Immunostimulatory Activity of CpG- Containing Oligodeoxynucleotides on Mouse Spleen Cells

Enhancing Radiosensitivity of Human Pulmonary Adenocarcinoma Cell Line A549 by Cpg Odn1826

In Vivo and in Vitro Study of Inhibition Effects of CpG Oligodeoxynucleotide on Renal Carcinoma Cell Proliferation and Tumor Growth

CpG Oligodeoxynucleotide Stimulates Protective Innate Immunity Against Human Renal Cell Carcinoma Xenografted in Nude Mice